Evofem signs exclusive SOLOSEC license for UAE, Kuwait, Saudi Arabia and other Middle East countries

Evofem Biosciences, Inc.

Exclusive 5-year license to develop, market, and sell SOLOSEC in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
Pharma 1 targets mid-2025 regulatory submission in UAE; must file within 3 months of agreement.
Consideration includes upfront payment, regulatory milestones, and sales-based milestones; supply at cost-plus.
SOLOSEC is FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
Expands existing Evofem-Pharma 1 partnership beyond PHEXXI to SOLOSEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.